Stivarga (regorafenib)

News alerts, weekly reports and conference planners

Company:

Amgen, Bayer

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
No biomarker	Glioblastoma	No biomarker	Glioblastoma	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
SDHB deletion	Gastrointestinal Stromal Tumor	SDHB deletion	Gastrointestinal Stromal Tumor	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
CRY1 rs1056560	Colorectal Cancer	CRY1 rs1056560	Colorectal Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 9 mutation	Gastrointestinal Stromal Tumor	KIT exon 9 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 17 mutation	Gastrointestinal Stromal Tumor	KIT exon 17 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 13 mutation	Gastrointestinal Stromal Tumor	KIT exon 13 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 18 mutation	Gastrointestinal Stromal Tumor	KIT exon 18 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KIT exon 14 mutation	Gastrointestinal Stromal Tumor	KIT exon 14 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2
KIT exon 17 mutation + KIT exon 18 mutation	Gastrointestinal Stromal Tumor	KIT exon 17 mutation + KIT exon 18 mutation	Gastrointestinal Stromal Tumor	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2
KIT mutation	Melanoma	KIT mutation	Melanoma	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2
INHBA rs2237432	Colorectal Cancer	INHBA rs2237432	Colorectal Cancer	regorafenib Sensitive: C3 – Early Trials regorafenib Sensitive : C3	regorafenib Sensitive: C3 – Early Trials regorafenib Sensitive : C3
FOXO3 rs12212067	Colorectal Cancer	FOXO3 rs12212067	Colorectal Cancer	regorafenib Resistant: C3 – Early Trials regorafenib Resistant : C3	regorafenib Resistant: C3 – Early Trials regorafenib Resistant : C3
PD-L1 expression	Colorectal Cancer	PD-L1 expression	Colorectal Cancer	regorafenib Sensitive: C3 – Early Trials regorafenib Sensitive : C3	regorafenib Sensitive: C3 – Early Trials regorafenib Sensitive : C3

Stivarga (regorafenib)

Associations
(65)

Associations
(65)

Stivarga (regorafenib)

Associations(65)

Associations(65)

Associations
(65)

Associations
(65)